Skip to main content

Paget's Disease of Bone

3
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
4 programs
2
1
Zoledronic acidPhase 4
Zoledronic AcidPhase 3
zoledronic acidPhase 3
Genetic Study of Families Affected by Paget's Disease of BoneN/A
Novartis
NovartisBASEL, Switzerland
1 program
Genetic Study of Families Affected by Paget's Disease of BoneN/A1 trial
Active Trials
NCT00747994Completed83Est. Sep 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisGenetic Study of Families Affected by Paget's Disease of Bone

Clinical Trials (1)

Total enrollment: 83 patients across 1 trials

NCT00747994NovartisGenetic Study of Families Affected by Paget's Disease of Bone

Genetic Study of Families Affected by Paget's Disease of Bone

Start: Sep 2007Est. completion: Sep 200883 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.